Ocular Therapeutix (OCUL) Convertible Debt (2019 - 2023)

Ocular Therapeutix has reported Convertible Debt for 5 years, with the latest figure at $9.1 million in Q4 2023.

• Convertible Debt for Q4 2023 came in at $9.1 million, down 68.21% year-over-year; the trailing twelve-month figure through Dec 2023 was $9.1 million (down 68.21% YoY), and the FY2023 annual result was $9.1 million, down 68.21% from the prior year.
• Convertible Debt rose to $9.1 million in Q4 2023, from $8.8 million in the prior quarter.
• Over five years, Convertible Debt peaked at $30.0 million in Q2 2023 and troughed at $8.8 million in Q3 2023.
• A 5-year average of $24.3 million and a median of $25.3 million in 2020 frame the typical range for Convertible Debt.
• The widest annual swing landed in 2020, when Convertible Debt increased 10.27%; it then slumped 68.87% in 2023.
• A 5-year view of Convertible Debt shows it stood at $24.3 million in 2019, then advanced by 0.01% to $24.3 million in 2020, then rose by 8.75% to $26.4 million in 2021, then gained by 8.75% to $28.7 million in 2022, then sank by 68.21% to $9.1 million in 2023.
• Per Business Quant data, the three most recent Convertible Debt figures were $9.1 million in Q4 2023, $8.8 million in Q3 2023, and $30.0 million in Q2 2023.